High Blood Pressure & Cardiovascular Prevention最新文献

{"title":"Arterial Hypertension and Kidney Function Decline in Systemic Sclerosis and Sjögren's Disease: A Longitudinal Comparative Study.","authors":"Antonietta Gigante, Chiara Pellicano, Emanuele Grilli, Elena Maria Di Virgilio, Angelica Gattamelata, Francesco Iannazzo, Rosario Cianci, Edoardo Rosato, Roberta Priori","doi":"10.1007/s40292-026-00825-1","DOIUrl":"https://doi.org/10.1007/s40292-026-00825-1","url":null,"abstract":"<p><strong>Introduction: </strong>Renal involvement is increasingly recognized in Systemic Sclerosis (SSc) and Sjögren's Disease (SjD). However, the association between hypertension and renal function decline in these conditions remains poorly understood.</p><p><strong>Aim: </strong>to compare renal function changes over time in patients with SSc and SjD; identify factors associated with clinically relevant renal function decline; and to evaluate whether the association between hypertension and renal function differs between the two diseases.</p><p><strong>Methods: </strong>We retrospectively analyzed patients with SSc and SjD, followed for up to 3 years. Renal function was assessed using estimated glomerular filtration rate (eGFR). Clinically relevant renal decline was defined as a reduction in eGFR ≥10 ml/min Multivariable logistic regression identified factors associated with renal function decline, including the interaction between diagnosis and hypertension.</p><p><strong>Results: </strong>A total of 238 patients were included (114 with SSc and 124 with SjD), with a median age of 55 years (IQR 45-65) in SSc and 57 years (IQR 48-66) in SjD. At baseline, SSc patients showed higher eGFR compared to SjD, but experienced a greater decline over time (median -6 vs -2.1 ml/min, p < 0.05). Overall, 33.8% of patients developed clinically significant renal decline. In multivariable analysis, hypertension was independently associated with renal function decline (OR 10.01, 95% CI 3.51-28.56, p < 0.001), whereas diagnosis was not. A significant interaction between diagnosis and hypertension was observed (OR 6.56, 95% CI 1.03-41.69, p = 0.046), indicating a stronger association between hypertension and renal function decline in SSc than in SjD. In subgroup analyses, hypertension was significantly associated with renal decline in SSc but not in SjD.</p><p><strong>Conclusions: </strong>Hypertension was independently associated with renal function decline, with a stronger association in SSc than in SjD. These findings warrant confirmation in prospective studies. Systemic Sclerosis, Sjögren's disease, Estimated Glomerular Filtration Rate; arterial hypertension.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149227764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in Office and Ambulatory Pulse Wave Analysis in Patients with White Coat Hypertension and Other Hypertension Phenotypes.","authors":"Ann-Kathrin Carolin Schäfer, Eva Maria Nuhn, Stephan Lüders, Clemens Grupp, Manuel Wallbach, Michael Johann Koziolek","doi":"10.1007/s40292-026-00830-4","DOIUrl":"https://doi.org/10.1007/s40292-026-00830-4","url":null,"abstract":"<p><strong>Introduction: </strong>Increased arterial stiffness is a sign of vascular damage; therefore, assessing it is crucial for evaluating cardiovascular risk. Arterial stiffness parameters such as pulse wave velocity (PWV) and augmentation index (at heart rate 75 bpm, AIX@75) were shown to correlate directly with blood pressure (BP).</p><p><strong>Aim: </strong>Since these parameters may consequently be altered in patients with white coat effect (WCE), this study examined differences in office and 24h measurements of these parameters across various BP phenotypes.</p><p><strong>Methods: </strong>In this multicenter cross-sectional study, conducted between 2018 and 2023 at three nephrology clinics, office and 24h BP measurements and pulse wave analysis (PWA) of 208 patients were examined.</p><p><strong>Results: </strong>189 patients were included; 48 were diagnosed with controlled hypertension (HTN), 63 with uncontrolled HTN, 22 with a masked HTN phenotype, 30 with WCE, of whom 11 had white coat HTN (WCH) and 19 had white coat uncontrolled HTN (WCUH), and 26 had normal BP. By definition, patients with WCE had significantly higher office peripheral and aortic BP than the respective 24h values (p<0.0001 each). Their AIX@75 was significantly higher on office (32.7±11.4%) than on 24h measurement (27.4±7.2%, p=0.0354), and they showed a significantly greater reduction in PWV between office and 24h measurement than normotensives and all other BP phenotypes (p_adj <0.0001 each).</p><p><strong>Conclusions: </strong>In patients with WCE, there are significant differences in arterial stiffness parameters between office and 24h measurements, suggesting that both measurement methods provide complementary hemodynamic information. Prospective studies are needed to determine the prognostic significance of these differences.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149215970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Adherence to Dihydropyridine Calcium-Channel Blockers: A Pharmacoepidemiologic Study.","authors":"Marco Capacci, Giulia Rivasi, Luca Degli Esposti, Carlo Fumagalli, Giuseppe Dario Testa, Simone Leonetti, Lisa Giannessi, Claudio Ferri, Andrea Ungar, Niccolò Marchionni","doi":"10.1007/s40292-026-00827-z","DOIUrl":"https://doi.org/10.1007/s40292-026-00827-z","url":null,"abstract":"<p><strong>Introduction: </strong>Low medication adherence contributes to uncontrolled cardiovascular (CV) risk.</p><p><strong>Aims: </strong>This study investigated 12- and 24-month adherence, all-cause mortality and CV events in subjects receiving originator or generic dihydropyridine calcium-channel blockers (CCBs) as recorded in administrative databases from Local Health Units across several Italian regions.</p><p><strong>Methods: </strong>We retrospectively analysed databases containing demographics and vital status, drug prescriptions, and hospital discharge diagnoses for more than 6 million individuals. Subjects receiving lercanidipine originator, generic lercanidipine, amlodipine originator, or generic amlodipine were included. Subjects with prior or occasional CCB use, inadequate follow-up time, chronic ischaemic heart disease or acute pulmonary heart disease, or switching between CCBs were excluded. Adherence was defined as a Proportion of Days Covered ≥ 80% at 12 and 24 months. Cox regression models estimated the association between treatments and a composite of all-cause mortality and CV events.</p><p><strong>Results: </strong>Adherence was assessed in 3,860 propensity-score-matched subjects (965/group), selected from 14,849 eligible subjects. Lercanidipine originator was associated with higher (p < 0.001) 12-month (43%) and 24-month (38%) adherence than generic lercanidipine (31 and 26%) and amlodipine originator (22 and 19%). The events analysis included 15,808 subjects. Compared with originator lercanidipine, originator amlodipine, generic lercanidipine and generic amlodipine were associated with 43%, 30% and 33% higher hazards of the composite outcome, respectively (corresponding 95% Confidence Intervals: 1.28-1.60, 1.10-1.55, 1.17-1.50).</p><p><strong>Conclusions: </strong>Medium-term adherence was low across all treatments. Originator lercanidipine was associated with the highest adherence, with lower adjusted hazards of the composite outcome and all-cause mortality compared to the other treatments.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149166683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"XLIII National Congress of the Italian Society of Hypertension (SIIA) National Congress of Hypertension Centers and Outpatient Clinics of Hypertension Pisa, 9-11 October 2026.","authors":"","doi":"10.1007/s40292-026-00818-0","DOIUrl":"10.1007/s40292-026-00818-0","url":null,"abstract":"","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149148195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pilot Randomised Controlled Trial Comparing Two Digital Solutions in the Management of Hypertensive Patients.","authors":"Luigi De Luca, Alessandro Croce, Davide Soranna, Antonella Zambon, Grzegorz Bilo, Gianfranco Parati, Martino F Pengo","doi":"10.1007/s40292-026-00823-3","DOIUrl":"https://doi.org/10.1007/s40292-026-00823-3","url":null,"abstract":"<p><strong>Introduction: </strong>Mobile health technologies may support hypertension management, yet comparative evidence between different digital platforms remains limited.</p><p><strong>Aim: </strong>This pilot randomized controlled trial aimed to compare the effectiveness, adherence, usability and patient satisfaction of two m-health solutions versus standard care on blood pressure (BP) control in patients with hypertension.</p><p><strong>Methods: </strong>In this open-label, single-centre pilot trial, adults with essential hypertension were randomised (1:1:1) to standard care, Digital Solution 1 (DS1) or Digital Solution 2 (DS2). Both digital interventions enabled home BP and body weight monitoring via connected devices and smartphone applications. The primary endpoint was the difference in office BP change from baseline to 6 months among groups, analyzed using linear mixed models. Secondary endpoints included changes in body weight, adherence to home BP and weight monitoring, and patient-reported usability and satisfaction. Quality of life and physical activity were assessed as exploratory outcomes.</p><p><strong>Results: </strong>A total of 65 patients were included and randomized whilst 49 completed the 6-month follow-up. No significant between-group differences at this time were observed in office systolic or diastolic BP trends (interaction p=0.44 and p=0.22, respectively). Adherence to home BP monitoring was higher with DS2 than DS1 (median adherent weeks 71% vs 11%, p=0.0002). Similarly, adherence to body weight monitoring was greater with DS2 (median 43% vs 11% of weeks, p=0.007). DS2 was also associated with higher usability and satisfaction scores. No significant differences were observed in body weight change, quality of life or physical activity.</p><p><strong>Conclusion: </strong>In this pilot study, m-health interventions did not improve office BP control compared with standard care. However, marked differences in adherence and usability between digital platforms were observed, underscoring the importance of system design and user experience in determining the effectiveness of digital strategies for hypertension management.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Antihypertensive De-escalation: A Secondary Analysis of Systolic Blood Pressure Intervention Trial (SPRINT).","authors":"Fanxing Du, Steven M Smith, Janie Coulombe, Mark S Segal, Adam P Bress, Tianze Jiao","doi":"10.1007/s40292-026-00822-4","DOIUrl":"https://doi.org/10.1007/s40292-026-00822-4","url":null,"abstract":"<p><strong>Introduction: </strong>Antihypertensive de-escalation-reducing the number of antihypertensive medications-is sometimes warranted but may increase cardiovascular risk.</p><p><strong>Aim: </strong>To evaluate the association of antihypertensive de-escalation with major adverse cardiovascular events (MACE) in the Systolic Blood Pressure Intervention Trial (SPRINT).</p><p><strong>Methods: </strong>Our secondary analysis of SPRINT included participants randomized to intensive (target systolic blood pressure [SBP] <120 mm Hg) vs. standard (target SBP <140 mm Hg) antihypertensive strategies. Before randomization, some patients underwent antihypertensive de-escalation to increase SBP into 130-180 mm Hg for eligibility. The exposure was antihypertensive de-escalation, defined as a reduction in the number of antihypertensive medications between screening and randomization; the control group included participants without such a reduction. The primary outcome was major cardiovascular events (MACE), comprising myocardial infarction, acute coronary syndrome, stroke, heart failure, or cardiovascular cause death.</p><p><strong>Results: </strong>The number of patients in de-escalation and control groups were 794 vs. 3,733 (standard arm) and 427 vs. 4,007 (intensive arm). De-escalation patients had higher baseline cardiovascular risk. In the standard arm (target SBP <140 mm Hg), de-escalation was followed by delayed treatment re-intensification, with only 52.9% of de-escalation patients returned to their medication count at screening visit after a mean of 358.0 days following randomization. In contrast, 76.6% of de-escalation patients in the intensive arm (target SBP <120 mm Hg) returned to their screening medication count, with a shorter mean time of 197.9 days. De-escalation followed by delayed treatment re-intensification under the standard treatment strategy was associated with an increased MACE risk (HR: 1.34, 95% CI: 1.04-1.74) than control patients. Conversely, no excess MACE risk was observed among de-escalation patients in the intensive arm, where treatment was promptly re-intensified after de-escalation under an intensive SBP target (<120 mm Hg).</p><p><strong>Conclusions: </strong>Antihypertensive de-escalation, followed by delayed treatment re-intensification, is associated with an increased risk of MACE. These findings reassure the benefit of continuous intensive SBP control and timely re-intensification treatment after de-escalation, especially in patients at high cardiovascular risk.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interventional Treatment of Arterial Hypertension in The Modern Era: An Updated Review from the Young Investigator Group of the European Society of Hypertension.","authors":"Yusuf Ziya Şener, Costantino Mancusi, Alexandr Ceasovschih, Andrej Belančić, Ariadni Menti, Christina Antza, Diana Ferrao, Jelena Petrović, Justine Huart, Karel Lábr, Ilaria Fucile, Marijana Vučković, Andrej Porcnik, Petra Sinigoj, Niki Katsiki","doi":"10.1007/s40292-026-00821-5","DOIUrl":"https://doi.org/10.1007/s40292-026-00821-5","url":null,"abstract":"<p><p>Achievement of blood pressure targets in hypertensive patients is a challenge for clinicians despite the different classes of drugs currently available. For this reason, taking advantage of the technological progress, new interventional strategies have been proposed. Each of these approaches acts on autonomic and vascular regulation, critical components of hypertension pathophysiology with the aim to recalibrate aberrant sympathetic activation and vascular dysfunction. Renal artery denervation is the only modality currently supported by guideline recommendations in selected patients. Baroreflex activation therapy, and carotid body modulation, thanks to good experimental results, are under evaluation as promising strategies. Concurrently, newer modalities, such as deep brain stimulation, cardiac neuromodulation, and arteriovenous shunts, are emerging with promising early data. The present narrative review provides an overview of interventional treatments for hypertension, describing their efficacy, mechanism of action, safety, and side effects. As clinical research progresses, there is the possibility that these techniques will emerge as promising treatment options for patients with resistant hypertension in the near future.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148900472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lean Mass Reduction During Glucagon-like Peptide-1 Receptor Agonists-Induced Weight Loss: Rethinking Its Clinical Significance.","authors":"Federica Moscucci, Giuliano Tocci, Giulia Nardoianni, Carmine Savoia, Vincenzo Contino, Gaetano Leo, Raffaella Bocale, Giovambattista Desideri, Francesco Baratta","doi":"10.1007/s40292-026-00819-z","DOIUrl":"https://doi.org/10.1007/s40292-026-00819-z","url":null,"abstract":"<p><p>The substantial weight loss achieved with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual incretin agonists has transformed the management of obesity and cardiometabolic risk. However, the accompanying reduction in lean mass has raised concerns regarding potential sarcopenia and impaired physical function, particularly in older adults. These concerns have become increasingly relevant as incretin-based therapies assume a central role in cardiovascular prevention. Importantly, reductions in lean mass measured by dual-energy X-ray absorptiometry and other body-composition techniques do not necessarily reflect deterioration in muscle quality, strength, or functional capacity. We propose that a substantial proportion of the observed decline in lean mass represents a physiological adaptation to the reduced mechanical loading associated with marked weight loss. Obesity imposes chronic biomechanical overload on weight-bearing musculature, promoting compensatory increases in muscle mass. Conversely, successful weight reduction lowers mechanical demands and may induce adaptive remodeling of antigravity muscles toward a new equilibrium appropriate for a lighter body. This interpretation is supported by established principles of unloading physiology derived from studies of immobilization, bed rest, and microgravity, as well as by emerging concepts linking body-weight sensing to musculoskeletal adaptation. We present a conceptual framework in which energy deficit, improvements in tissue composition, and mechanical unloading act as complementary contributors to lean mass reduction during GLP-1 RAs therapy. We also propose testable predictions that may help distinguish adaptive remodeling from pathological muscle loss (Fig. 1). From a cardiovascular prevention perspective, the key question may not be whether lean mass decreases during successful obesity treatment, but whether these changes impair physical function or diminish the substantial cardiometabolic benefits of weight reduction. Recognizing mechanical unloading as an underappreciated explanatory framework for interpreting lean mass loss during incretin-based therapy may improve risk-benefit assessment and redirect attention toward clinically meaningful outcomes, including muscle strength, physical performance, mobility, and cardiovascular health.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148900407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics and Determinants of Pulse Wave Velocity in Super Normal Vascular Aging (SUPERNOVA) Patients.","authors":"Christina Antza, Nikolaos Kakaletsis, Eugenia Gkaliagkousi, Christos Savopoulos, Vasilios Kotsis","doi":"10.1007/s40292-026-00801-9","DOIUrl":"10.1007/s40292-026-00801-9","url":null,"abstract":"<p><strong>Introduction: </strong>Super Normal Vascular Aging (SUPERNOVA) describes individuals whose vascular system remains protected, despite exposure to cardiovascular risk factors. Understanding the determinants of arterial stiffness in this population may provide valuable insights into protection mechanisms.</p><p><strong>Aim: </strong>This study aims to investigate the key features of SUPERNOVA individuals and examine factors associated with carotid-femoral pulse wave velocity (cf-PWV) across different age subgroups.</p><p><strong>Methods: </strong>This cross-sectional study included individuals referred to a Hypertension Center for blood pressure (BP) evaluation. SUPERNOVA status was defined based on cf-PWV values lower than the age-expected averages derived from European population. Clinical, laboratory, and ambulatory BP measurements were recorded.</p><p><strong>Results: </strong>From a total cohort of 829 participants, 37.2% (n = 308) met the SUPERNOVA criteria. The mean age was 42.7 ± 25years (57.9% females). The population present normal BP parameters during day, night and 24 h, almost in all age decades. The mean cf-PWV presented the lowest value (5.2 ± 0.5 m/s) for the youngest age group (< 30years) and the highest (9.3 ± 1.0 m/s) for the older (≥ 70years). The prevalence of hypertension, obesity, smoking, and dyslipidemia was lower among elderly SUPERNOVA individuals (≥ 70years) compared to younger groups. Multivariate analysis revealed that age (B: 0.06, p < 0.001), LDL cholesterol (B: 0.009, p = 0.001), and 24-hour systolic BP (B: 0.031, p = 0.005) were independently associated with higher cf-PWV, whereas 24-hour diastolic BP (B: - 0.047, p = 0.003) was inversely associated among SUPERNOVA patients.</p><p><strong>Conclusion: </strong>This study highlights key characteristics of SUPERNOVA individuals and suggests that LDL cholesterol and 24-hour systolic BP are crucial factors influencing arterial stiffness. These findings may help identify strategies to preserve vascular health and delay arterial aging.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"547-555"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13547176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impaired Intracranial Compliance: A New Hypertension-Mediated Brain Organ Damage?","authors":"Mikaelle C Correia, Sayuri Inuzuka, Matheus Martins da Costa, Ana Luiza Lima Sousa, Priscila Valverde de Oliveira Vitorino, Gustavo Frigieri, Polyana Vulcano de Toledo Piza, Audes Diógenes de Magalhães Feitosa, Rodrigo Bezerra, Mayara Cedrim Santos, Marco Antônio Mota-Gomes, Andréa Araujo Brandão, Erika Maria Gonçalves Campana, Eduardo Costa Duarte Barbosa, Christian da Silva Dal Pont, Antonio Coca, Weimar K S Barroso","doi":"10.1007/s40292-026-00804-6","DOIUrl":"10.1007/s40292-026-00804-6","url":null,"abstract":"<p><strong>Introduction: </strong>Hypertension-mediated organ damage (HMOD) is well established in the heart, kidneys, and vasculature; however, early markers of cerebral involvement remain poorly defined.</p><p><strong>Aim: </strong>This multicenter, cross-sectional Brazilian study investigated impaired intracranial compliance (ICC) across hypertension (HT) stages in adults without neurological disease or antihypertensive therapy, aiming to characterize early cerebral hemodynamic changes potentially related to hypertension-mediated brain organ damage.</p><p><strong>Methods: </strong>ICC was assessed noninvasively from intracranial pressure (ICP) waveforms using the P2/P1 ratio and time-to-peak (TTP).</p><p><strong>Results: </strong>A total of 252 participants were included (52.4% men, 87.7% < 65 years). Mean P2/P1 and TTP values were 1.32 and 0.25, respectively. Significant differences were found between prehypertension and stage 2 HT (p < 0.001) and between stage 1 and 2 (p < 0.05) for P2/P1, as well as between prehypertension and stage 2 for TTP (p < 0.05). The Jonckheere-Terpstra test confirmed a progressive increase in both parameters across HT stages. Women presented higher values of P2/P1 and TTP in all stages.</p><p><strong>Conclusions: </strong>These findings suggest early and progressive impairment of ICC with increasing blood pressure, supporting its potential relevance as an early marker of cerebrovascular dysfunction, especially in women.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"583-592"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13547157/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148054404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}